Sign in to view content

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial

Diana V Do, MD, FASRS

Video
Published 2024

Related

Plasma Arginine and Citrulline are Elevated in Diabetic Retinopathy
Milam A. Brantley, MD, PhD
On Demand Cases, Courses, and Papers
2019
Combination Therapy With Intravitreal Nesvacumab+Aflibercept in Diabetic Macular Edema: The Phase 2 RUBY Trial
Jeffrey S. Heier, MD
Annual Meeting Talks
2018
Episode 204: Journal Club Featuring AMD Cost Analysis, DME Real-World Trends, PVDs and Retinal Breaks
Jayanth Sridhar, MD
Member Podcasts
2019

Category: Retinal Vascular Disease

See more